The trial is expected to enroll approximately 1,500 children 5 to 17 months of age, starting in late 2017. Read more...
MVI PortfolioWe strategically use our resources to support and advance a range of vaccine approaches that target both humoral and cellular immunity.
Evaluation technology projectsWe partner to develop and optimize new assays and challenge models and support reference and service laboratories. Find out more about our evaluation technologies by clicking on each project box below.
RTS,SThe World Health Organization (WHO) recommends pilot implementations for GSK's malaria vaccine candidate RTS,S (also known as MosquirixTM).